九典制药跌2.05%，成交额1.27亿元，主力资金净流出1540.57万元

Core Viewpoint - JiuDian Pharmaceutical's stock has experienced a decline of 4.99% year-to-date, with a recent drop of 2.05% on November 17, 2023, indicating potential challenges in market performance [1]. Financial Performance - For the period from January to September 2025, JiuDian Pharmaceutical reported a revenue of 2.268 billion yuan, representing a year-on-year growth of 5.69%. However, the net profit attributable to shareholders decreased by 9.64% to 406 million yuan [2]. - Cumulative cash dividends since the company's A-share listing amount to 450 million yuan, with 346 million yuan distributed over the past three years [3]. Shareholder and Market Activity - As of September 30, 2025, the number of shareholders decreased by 10.37% to 34,700, while the average number of circulating shares per person increased by 11.56% to 10,645 shares [2]. - The stock's trading activity on November 17 showed a net outflow of 15.41 million yuan from major funds, with significant selling pressure observed [1]. Company Overview - JiuDian Pharmaceutical, established on January 19, 2001, and listed on October 10, 2017, is primarily engaged in the research, production, and sales of pharmaceutical products. The revenue composition includes 82.47% from drug formulations, 7.65% from active pharmaceutical ingredients, and 6.03% from pharmaceutical excipients [1].